Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women
Brief Summary: Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection in HIV-infected MSM and HIV-infected women.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
B: Arm Label: Girls 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Boys 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls and Boys 9 to 14 Years V503 at Months 0 and 12; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls 9 to 14 Years V503 at Months 0, 2, and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Young Women 16 to 26 Years V503 at Months 0, 2, and 6; Type: ACTIVE_COMPARATOR; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Intervention Type: BIOLOGICAL; Name: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine); Assigned to Arm(s): Boys 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0, 2, and 6, Girls and Boys 9 to 14 Years V503 at Months 0 and 12, Young Women 16 to 26 Years V503 at Months 0, 2, and 6
C: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose
D: Arm Label: Quadrivalent HPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent HPV Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine for Male Participants Only, Biological: Placebo Vaccine for Female Participants Only | Intervention Type: BIOLOGICAL; Name: Quadrivalent HPV Vaccine; Assigned to Arm(s): Quadrivalent HPV Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Male Participants Only; Assigned to Arm(s): Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine for Female Participants Only; Assigned to Arm(s): Placebo Vaccine

Answer: D